Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression

Gene Therapy

Volumn 4, Issue 5, 1997, Pages 473-482

  Michou, A I ^a   Santoro, L ^a   Christ, M ^a   Julliard, V ^b   Pavirani, A ^a   Mehtali, M ^a  

^a TRANSGENE S A   (France)

^b INSTITUT COCHIN   (France)

Author keywords

Adenovirus; Factor IX; Immune response; Mouse; galactasidase

Indexed keywords

ANTIBODY; ANTIGEN; BETA GALACTOSIDASE; BLOOD CLOTTING FACTOR 9; VIRUS ANTIGEN; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); DNA VIRUSES;

EID: 0030999469     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300412     Document Type: Article

References (48)

1. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 1988; 6: 616-629.
2. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. In: Ellis RW (ed). Vaccines. New Approaches to Immunological Problems. Butterworth-Heinemann: London, 1992, pp 363-390.
3. Trapnell BC. Adenoviral vectors for gene transfer. Adv Drug Deliv Rev 1993; 12: 185-199.
4. Horwitz MS. Adenoviridae and their replication. In: Fields BN et al (ed). Virology, 2nd ed. Raven Press: New York, 1990, pp 1679-1721.
5. Philipson L. Structure and assembly of adenoviruses. Curr Top Microbiol Immunol 1983; 109: 1-52.
6. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
7. Chartier C et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
8. Graham FL, Prevec L. Manipulation of adenovirus vectors. Meth Mol Biol 1991; 7: 109-128.
9. Imler JL et al. An efficient procedure to select and recover recombinant adenovirus vectors. Gene Therapy 1995; 2: 263-268.
10. Ketner G Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci USA 1994; 91: 6186-6190.
11. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
12. Imler JL et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Therapy 1996; 3: 75-85.
13. Jones N, Shenk T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 1979; 76: 3665-3669.
14. Connelly S et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-193.
15. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
16. Kozarsky KF et al In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenovirus. J Biol Chem 1994; 269: 13695-13702.
17. Le Gal La Salle G et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988-990.
18. Lemarchand P et al. Adenovirus-mediated gene transfer of a recombinant α1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 1992; 89: 6482-6486.
19. Li Q et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409.
20. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
21. Smith TAG et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 392-402.
22. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J din Invest 1992; 90: 626-630.
23. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tracts of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
24. Knowles MR et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 1995; 333: 823-831.
25. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
26. Dai Y et al Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
27. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenovirus defective in E2a. Hum Gene Ther 1994; 5: 1217-1229.
28. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
29. Yang Y, Ertl HCJ, Wilson JM. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
30. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
31. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
32. Yang Y et al. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
33. Yang Y, Qin L, Ertl HJC, Wilson JM. Cellular and humoral immune response to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
34. Zsengeller ZK et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
35. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
36. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4 and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6: 1575-1586.
37. Wang Q, Jia XC, Finer MH. A packaging cell line for the propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Therapy 1995; 2: 775-783.
38. Yeh P et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-565.
39. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodencient inbred strains. Gene Therapy 1995; 2: 151-155.
40. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
41. Geffner JR. Antibody-dependent cell-mediated cytotoxicity. In: Roitt IM, Delves PJ (eds). Encyclopedia of Immunology. Academic Press. London, 1992, pp 100-102.
42. Andriole GL et al. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on analysis of congenitally immunodeficient mice. J Immunol 1985; 135: 5-7
43. Bosma GC, Custer MC, Bosma MJ. A severe combined immuno-deficiency mutation in the mouse. Nature (Lond) 1983; 301: 527-530.
44. Yoshikai Y, Reis MD, Mak TW. Athymic mice express a high level of functional γ-chain but greatly reduced levels of α and β chain T cell receptor messengers. Nature (Loud) 1986, 324: 482-485.
45. Balland A et al. Characterization of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector. Eur J Biochem 1988; 172: 565-572.
46. Adra C N, Boer PH, McBurney MW. Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. Gene 1987; 60: 65-74.
47. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mot biol 1967; 26: 365-369.
48. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.